Patel CG - Search Results

1

Post-CAR T-Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B-Cell Lymphoma.

Ababneh HS, Frigault MJ, Ng AK, Patel CG. Ababneh HS, et al. Among authors: patel cg. Hematol Oncol. 2025 Jan;43(1):e70025. doi: 10.1002/hon.70025. Hematol Oncol. 2025. PMID: 39688000

2

Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy.

Ababneh HS, Abramson JS, Johnson PC, Patel CG. Ababneh HS, et al. Among authors: patel cg. Radiother Oncol. 2022 Oct;175:65-72. doi: 10.1016/j.radonc.2022.08.007. Epub 2022 Aug 8. Radiother Oncol. 2022. PMID: 35952976 Review.

3

Leaving Lytic Lesions-Is There New Role for Radiation in Multiple Myeloma in the CAR T Era?

Ababneh HS, Raje NS, Yee AJ, Patel CG. Ababneh HS, et al. Among authors: patel cg. Pract Radiat Oncol. 2022 Sep-Oct;12(5):367-369. doi: 10.1016/j.prro.2022.05.002. Pract Radiat Oncol. 2022. PMID: 36058616 No abstract available.

4

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy.

Ababneh HS, Ng AK, Frigault MJ, Abramson JS, Johnson PC, Jacobson CA, Patel CG. Ababneh HS, et al. Among authors: patel cg. Haematologica. 2023 Nov 1;108(11):2972-2981. doi: 10.3324/haematol.2023.282804. Haematologica. 2023. PMID: 37317884 Free PMC article.

5

Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy.

Ababneh HS, Frigault MJ, Patel CG. Ababneh HS, et al. Among authors: patel cg. Hematol Oncol. 2024 Jan;42(1):e3221. doi: 10.1002/hon.3221. Epub 2023 Sep 7. Hematol Oncol. 2024. PMID: 37679941 No abstract available.

6

Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy.

Ababneh HS, Yee AJ, Raje NS, Martin S, Frigault MJ, Ng AK, Patel CG. Ababneh HS, et al. Among authors: patel cg. Radiother Oncol. 2023 Dec;189:109933. doi: 10.1016/j.radonc.2023.109933. Epub 2023 Sep 30. Radiother Oncol. 2023. PMID: 37778534

7

Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma.

Ababneh HS, Ng AK, Abramson JS, Soumerai JD, Takvorian RW, Frigault MJ, Patel CG. Ababneh HS, et al. Among authors: patel cg. Hematol Oncol. 2024 Jan;42(1):e3231. doi: 10.1002/hon.3231. Epub 2023 Oct 5. Hematol Oncol. 2024. PMID: 37795759

8

Radiation therapy as bridging and salvage strategy among patients with secondary central nervous system lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy.

Ababneh HS, Frigault MJ, Ng AK, Patel CG. Ababneh HS, et al. Among authors: patel cg. Hematol Oncol. 2024 Jan;42(1):e3243. doi: 10.1002/hon.3243. Epub 2023 Dec 16. Hematol Oncol. 2024. PMID: 38103211 No abstract available.

9

Radiotherapy as a bridging strategy for patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.

Ababneh HS, Ng AK, Frigault MJ, Jacobson CA, Patel CG. Ababneh HS, et al. Among authors: patel cg. Am J Hematol. 2024 Sep;99(9):1837-1840. doi: 10.1002/ajh.27409. Epub 2024 Jun 11. Am J Hematol. 2024. PMID: 38860643 No abstract available.

10

Adaptive bridging radiation therapy for relapsed/refractory B-cell lymphoma patient undergoing CAR T-cell therapy: Case report.

Ababneh HS, Connor Johnson P, Pursley J, Patel CG. Ababneh HS, et al. Among authors: patel cg. Clin Transl Radiat Oncol. 2024 Jul 30;48:100832. doi: 10.1016/j.ctro.2024.100832. eCollection 2024 Sep. Clin Transl Radiat Oncol. 2024. PMID: 39185000 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

82 results

Search Page

Filters